BACKGROUND Methamphetamine is one of the most toxic of the drugs of abuse, which may reflect its distribution and accumulation in the body. However no studies have measured methamphetamine's organ distribution in the human body. METHODS Positron Emission Tomography (PET) was used in conjunction with [(11)C]d-methamphetamine to measure its whole-body distribution and bioavailability as assesse...

OBJECTIVE 1) To investigate the relationship between NrCAM polymorphisms and methamphetamine abuse in an ethnically homogenous Korean population. 2) To further support our findings by investigating the association among NrCAM gene variants, certain personality traits, and addictive symptoms of methamphetamine abusers. METHODS Thirty-seven male methamphetamine abusers (age=43.3±7.8) and30 non-...

Methamphetamine is the second most widely used illicit drug worldwide. More than 290 tons of methamphetamine was synthesized in the year 2005 alone, corresponding to approximately ~3 billion 100 mg doses of methamphetamine. Drug addicts abuse high concentrations of methamphetamine for months and even years. Current reports in the literature are consistent with the interpretation that methamphet...

Little research exists on effective strategies to prevent methamphetamine production, distribution, sales, use, and harm. As a result, prevention practitioners (especially at the local level) have little guidance in selecting potentially effective strategies. This article presents a general causal model of methamphetamine use and harms that reflects the available findings from either research s...

Pregnant methamphetamine users who leave substance use treatment against professional advice may be at risk of poorer health outcomes. To examine the hypothesis that methamphetamine use during pregnancy may be associated with leaving substance use treatment against professional advice, the 2006 Treatment Episode Data Set was analyzed. A logistic regression adjusting for age, race, service setti...

Relapse rates following current methamphetamine abuse treatments are very high (∼40-60%), and the neuropsychiatric impairments (e.g., cognitive deficits, mood disorders) that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates. Pharmacotherapeutic development of medications to treat addiction has focused on neurotransmitter systems wit...

AIMS To examine how race and methamphetamine legislation are associated with changes in cocaine and methamphetamine use among untreated rural stimulant users. DESIGN A longitudinal study of stimulant users identified through respondent-driven sampling. SETTING Rural areas of three US states. PARTICIPANTS Participants at baseline were current users of methamphetamine and/or cocaine. MEAS...

A B S T R A C T Abstract- Methamphetamine has rapidly become more prominent in Iran, which is now second most common drug behind heroin. Moreover, initiation of methamphetamine abuse is a major cause of failure of opioid treatment programs such as Methadone maintenance treatment. This calls for development of more effective treatment methods for methamphetamine addiction, and especially develop...

Lobeline, a nicotinic receptor antagonist and neurotransmitter transporter inhibitor, is a candidate pharmacotherapy for methamphetamine abuse. meso-Transdiene (MTD), a lobeline analog, lacks nicotinic receptor affinity, retains affinity for vesicular monoamine transporter 2 (VMAT2), and, surprisingly, has enhanced affinity for dopamine (DA) and serotonin transporters [DA transporter (DAT) and ...

Some structural analogues of amphetamine are now important drugs of abuse in Thailand. The utility of the Roche Abuscreen ONLINE reagent amphetamine immunoassay test kit to detect these analogues was studied. The test showed high cross-reactivity to 3,4-methylenedioxyamphetamine (MDA), but low cross-reactivity to its parent drugs, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxye...